Bridgeway Capital Management Inc. Grows Position in Marinus Pharmaceuticals Inc (MRNS)
Bridgeway Capital Management Inc. increased its position in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 93.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,706 shares of the biopharmaceutical company’s stock after acquiring an additional 54,100 shares during the period. Bridgeway Capital Management Inc. owned approximately 0.28% of Marinus Pharmaceuticals worth $1,117,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRNS. Bank of New York Mellon Corp lifted its stake in Marinus Pharmaceuticals by 190.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock valued at $754,000 after buying an additional 69,863 shares in the last quarter. Alps Advisors Inc. purchased a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth $416,000. Trexquant Investment LP purchased a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth $102,000. VHCP Management II LLC purchased a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth $2,441,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth $141,000. Institutional investors and hedge funds own 68.70% of the company’s stock.
Shares of MRNS opened at $5.31 on Friday. The firm has a market capitalization of $183.17 million, a P/E ratio of -6.64 and a beta of 3.18. Marinus Pharmaceuticals Inc has a twelve month low of $3.31 and a twelve month high of $10.54.
MRNS has been the topic of a number of recent analyst reports. BidaskClub raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 30th. Cantor Fitzgerald reissued a “buy” rating and set a $19.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, September 17th. Mizuho reissued a “buy” rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 25th. ValuEngine lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 6th. Finally, Zacks Investment Research raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $19.67.
Marinus Pharmaceuticals Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Featured Story: What is a Roth IRA?
Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals Inc (NASDAQ:MRNS).
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.